Introduction
Deep venous thrombosis (DVT) and pulmonary embolism remain a common cause of inpatient morbidity and mortality, especially in patients who are immobilized for long periods of time. DVT of the lower limbs tend .to dev:l?p in patients with the classic triad of risk factors: immobility of the lower limbs, endothelial injury and hypercoagulability. These risk factors are present in all victims of str~ke and neurological injury, and such patients are thus at high risk of DVT and the serious complication of pulmonary embolism. Despite this, there is little evidence av~ilab~e concerning the incidence of venous thromboembolism 10 stroke and the risks and benefits of various treatment modalities in its prevention. Most reviews concentrate on the prevention of venous thromboembolism in surgical patients, but 75% of fatal pulmonary emboli occur in patients who have not had surgery.l? Medical conditions carrying a high risk of DVT include stroke, myocardial in~arction, cancer and septicaemia, and in many cases the episode of pulmonary embolism causing death may simply hasten an inevitable demise. About two-thirds of people dying from pulmonary embolism would probably have died within a short time period from an underlying serious illness.' Those patients who fully recover from their episode of veno~s thromboembolism may still suffer from a chronic postphlebitic syndrome in the affected leg, characteriz~d by pain, swelling, chronic dermatitis and venous ulceration. true incidence. More accurate data come from a Swedish community-based prospective study where a venographically defined DVT occurred with an incidence of approximately 1.6/1000 population," The incidence of fatal pulmonary embolism is probably about 0.6/1 000 population." Gillum" used national (USA) data to document changes in the number of hospital discharges with the diagnosis of DVT and pulmonary embolism from 1970 to 1985. The rate of pulmonary embolism in those aged less than 65 years declined by over 40%, whilst in those aged over 65 years the decline was more modest at about 15%, emphasizing the persistent importance of this condition in the age group at greatest risk of stroke.
Studies from within a hospital population suggest that about 10% of those presenting with DVT have stroke as their predominant diagnosis." Other risk factors for DVT are listed in Table I ; not surprisingly, many of these are common to both stroke and DVT. For example, the risk of DVT rises with increasing age (as shown in Figure I ) and over 75% of stroke victims are aged over 65 years. 
Epidemiology of venous thromboembolism in acute stroke
Another way of assessing the relationship between stroke and DVT is to examine the frequency of DVT and pulmonary embolism in patients suffering acute stroke. Ferriar described in 1810 the clinical features of a DVT in a patient with a paralysed leg.!" but the association was not well recognized for many years. Warlow et alii found that 53% of 76 stroke patients had a DVT detectable on radioactive fibrinogen scanning in their paralysed leg compared with a 7% incidence of DVT in the contralateral limb. Most of the DVTs developed within 2-5 days of stroke onset, although follow-up in this study was for only 14 days after stroke onset. Seven out of the 76 patients (9%) developed a pulmonary embolus (diagnosed at autopsy or on unequivocal clinical criteria) and two of these were fatal. A further five patients had a diagnosis of probable pulmonary embolism. Similar results were found in an Italian study where DVT occurred in 38% of ischaemic stroke patients, and pulmonary embolism in 12% of stroke patients overall (total number of strokes 43). 12 Other postmortem and hospital-based studies looking at the frequency of venous thromboembolism in stroke patients are shown in Table 2 . Pulmonary embolism accounts for 5-13% of early deaths after stroke (within 30 days of stroke onset). In most of the studies death within the first week after stroke is related to neurological injury, whilst complications such as pneumonia and pulmonary embolism account for the majority of deaths thereafter. Figure 2 illustrates this with data from one postmortem study of a community-based stroke register."
Of prime clinical importance is that pulmonary embolism may not be correctly diagnosed before death. Only 16-38% of pulmonary emboli found on autopsy are correctly diagnosed antemortem, and this percentage of correct antemortem diagnosis tends to decline with increasing age." Deaths from pulmonary embolism may also occur late in ambulant stroke victims. Studies performed in a rehabilitation hospital setting suggest that DVT occurs in up to 30% of rehabilitation subjects," and pulmonary embolism is not uncommon.
Pathogenesis of deep venous thrombosis and pulmonary embolism in acute stroke
Thrombus formation in the deep veins of the lower limb occurs with stasis or slowing of blood flow, which may also be associated with endothelial damage predisposing to platelet activation and coagulation and impairment of fibrinolysis. Venous stasis is probably the most important factor predisposing to DVT formation in the paralysed lower limb." and accounts for the predominance of DVT in the paralysed limb (53% incidence vs 7% in the nonparalysed limb in one study"). Stasis of blood in the deep veins occurs due to dependency and loss of the normal muscle pump action on the veins of the soleal plexus with muscle paralysis. Thrombi tend to start in the cusps of valves of the deep venous system, possibly related to platelet adherence at the site of endothelial injury related to hypoxia." Systemic activation of platelets and coagulation is seen in patients with both ischaemic and haemorrhagic stroke and this hypercoagulable state contributes to the formation of localized venous thrombi. 16 The mechanisms described above are not unique to patients with ischaemic stroke and those with subarachnoid or intracerebral haemorrhage are also at high risk of venous thromboembolism.
Venous thrombi tend to form in the soleal plexus of the calf and about 20% will propagate proximally into the popliteal, femoral and iliac systems. A large popliteal, femoral or iliac vein thrombus may be dislodged and embolize proximally to lodge in the pulmonary arteries of the lungs, producing acute pulmonary hypertension and sudden death if sufficient pulmonary arterial occlusion occurs (about 20% of cases of pulmonary embolism). Smaller emboli tend to lodge in the periphery of the lung parenchyma, producing pulmonary infarcts which may be associated with one or more of dyspnoea, pleuritic chest pain, cough, haemoptysis and fever.
Prevention of deep venous thrombosis and pulmonary embolism in acute stroke
Methods to prevent DVT have not been well tested in acute stroke despite the high prevalence of this complication in all types of stroke. Techniques used to prevent DVT are directed at one or more of the precipitants of thrombus formation as outlined in Table 3 . Some prophylactic strategies may also be unsuitable for some types of stroke (e.g. anticoagulation for cerebral haemorrhage), and it is difficult to generalize to all patients from the results of individual studies. Furthermore, many studies have used the endpoint of DVT as detected by screening tests such as radioactive labelled fibrinogen as a surrogate for the more serious complication of pulmonary embolism, and this mayor may not be appropriate. Mechanical methods of preventing DVT Simple measures such as leg elevation and early mobilization have not been formally tested in randomized controlled trials (RCT) or epidemiological observations; however, it seems likely that such therapy is helpful in the prevention of complications of immobilization such as venous thromboembolism. Electrical calf stimulation has been extensively used intraoperatively and in unconscious patients to prevent DVT, but is unsuitable for prolonged use in the conscious patient."
Devices to apply external pressure to a dependent limb and thus facilitate venous emptying have appeal in that they may prevent venous stasis, the major factor predisposing to thrombus formation. This approach was first suggested by Piere Dionis in the sixteenth century, but it was not until 1949 that Osborn and Wright found that application of elastic stockings accelerated venous return from the lower limb." This mechanism of action has been difficult to demonstrate experimentally, but intermittent compression via an external pneumatic device may simulate the normal venous pumping action of contracting muscles' and be more effective than continuous application of pressure such as is achieved with elastic bandaging or graduated compression stockings. External compression may also stimulate clot fibrinolysis, as measured by changes in euglobulin clot lysis time, possibly through the production of endogenous plasminogen activator."
Graded elastic compression stockings such as the TED (thromboembolism deterrent) stocking have not been tested in stroke but appear to reduce the risk of DVT in a wide variety of surgical patients. A formal meta-analysis of 11 such randomized controlled trials comparing graduated compression stockings with control showed that DVT, as diagnosed by radioactive fibrinogen scanning, was reduced by 68% (95% confidence limits: 53-73%), with the absolute risk of DVT being reduced from 17.6% to 6.2%.20 In addition, the number of pulmonary emboli was also reduced in the treatment group (two of 178 patients) versus control (nine of 183 patients). The diagnosis of pulmonary embolus is bedevilled by the uncertainty of current methods of diagnosis and the difficulty of systematically applying a screening test such as lung scanning. One of the RCTs in the meta-analysis studied the use of elastic stockings in neurosurgical patients, and found that in this category of patient DVT was reduced by 56% (a result compatible with the overall result), supporting their use in stroke patients." If such stockings are incorrectly applied or are the wrong size, there is a risk of causing a tourniquet effect which impairs venous return and may even cause arterial compromise.
Pneumatic compression devices vary in sophistication, but usually consist of a series of plastic bladders which are fixed over the lower limbs and are sequentially inflated and deflated to produce a pumping action to maintain venous flow in the lower limbs. Such devices can be comfortably worn whilst in bed and easily removed or disconnected to allow ambulation. Pneumatic compression devices have been tested extensively in neurosurgical and urological patients where anticoagulant treatment such as low-dose heparin is relatively contraindicated due to the risk of haemorrhage. Four well-designed RCTs in neurosurgical patients have confirmed the efficacy of pneumatic compression in preventing DVT (approximately 25% incidence in control reduced to approximately 10% in treated group), although data on the effect on pulmonary embolism are scanty." Only one small study (26 subjects) tested pneumatic compression devices in acute stroke, and the results were inconclusive, although treatment was given for only 9 h each day." Turpie et al 2 1 compared an intermittent compression device plus graduated compression stockings with graduated compression stockings alone in an RCT of neurosurgical patients and found no additional benefit from pneumatic compression (9% rate of DVT in combined group vs 8.8% stockings alone), but the numbers are too small for statistical certainty.
Physical methods of prophylaxis against DVT are clearly effective in neurosurgical patients and there is good reason to assume that they would also be effective in stroke patients with little in the way of complications or side-effects. In patients with cerebral haemorrhage they can be safely applied without fear of worsening or precipitating new cerebral haemorrhage.
Dihydroergotamine (a potent venous and arterial vasoconstrictor) has been used in some surgical studies to prevent DVT, but is probably contraindicated in stroke patients because of the risk of worsening cerebral blood flow and exacerbating coexistent coronary artery disease.
Heparin and anticoagulation
Low-dose unfractionated heparin has been extensively tested in acute ischaemic stroke, and reliable data exist confirming its efficacy in preventing DVT. The recent Cochrane Collaboration overview of eight RCTs suggests an 81% reduction in odds of DVT with heparin use early in acute stroke (incidence 54% in control vs 17% in treatment group)." Scanty data are available on confirmed pulmonary embolism suggesting a possible reducton (4.1% in control vs 2.3% in treatment), but this is not statistically significant. The unanswered question remains whether or not these favourable reductions in DVT are outweighed by an increased risk of bleeding. The preliminary results suggest a potential reduction in DVT of up to 300 and pulmonary embolism of up to 40 per 1000 patients treated, versus a potential increase in intracranial haemorrhage of up to 120 and deaths of up to 400 per 1000 patients treated." Figure 3 Vascular Medicine 1996; 1: [207] [208] [209] [210] [211] [212] summarizes the data available from a previous overview," where the most common dose of heparin used was 5000 units thrice daily. Further data on the risks and benefits of unfractionated heparin in acute ischaemic stroke will come from the International Stroke Trial when data on the effect of heparin on pulmonary embolism, bleeding and mortality from over 20 000 patients will be available.
Low-dose unfractionated heparin has also been used in one small RCT of patients with intracerebral haemorrhage without high complication rates," although most clinicians are probably hesitant to use such an agent in this group of patients.
Low molecular weight (LMW) heparin and heparinoids are purified forms of heparin which are more potent and specific antagonists of factor Xa, with a theoretically reduced risk of haemorrhage compared to unfractionated heparin. Such properties could be very useful in ischaemic stroke where the absolute risk of DVT is high (about 50%), and the consequences of bleeding are serious (cerebral haemorrhage). LMW heparinoids have been extensively tested in RCTs of DVT prophylaxis in general and orthopaedic surgical patients where the odds of DVT were reduced by 69% (95% confidence limits: 60-78%) compared to control therapy." Four RCTs studied the use of LMW heparinoids in the prevention of DVT in acute ischaemic stroke. Indirect comparisons with unfractionated heparin showed a similar degree of effectiveness (75% reduction with LMW heparin vs 81% reduction with unfractionated heparin)." More reliable direct randomized comparisons have been performed between a LMW heparinoid (danaparoid) and unfractionated heparin with the odds of DVT reduced by 48% (95% confidence limits: 14-69%) in the danaparoid treated group compared to unfractionated heparin (absolute reduction 22% to 13%). 28 There are few data on pulmonary embolism and bleeding sideeffects, although the overview on DVT prophylaxis in surgical patients suggested no major excess of haemorrhage with the LMW heparin regimen compared to unfractionated heparin (odds ratio 1.06 with 95% confidence limits of 0.93-1.2).27 Potentially, LMW heparinoids could reduce the absolute risk of DVT by 80 events per 1000 patients treated and of pulmonary embolism by 10/1000 compared to unfractionated heparin, but at the expense of increasing death by 10/1000 and intracranial haemorrhage by 511000. 28 The two agents need further detailed study in large RCTs.
Antiplatelet agents
Antiplatelet drugs include aspmn, hydroxychloroqine, ticlopidine and aspirin + dipyridamole have been demonstrated to reduce the odds of DVT by 39% (95% confidence limits: 29-49%) and of pulmonary embolism by 64% (95% confidence limits: 44-84%) in patients at high risk because of recent orthopaedic or general surgery and in high-risk medical patients." Data in patients with acute ischaemic stroke are scanty and come from only two small studies (both unpublished) which were included in the recent Cochrane Collaboration overview. The odds of DVT with antiplatelet therapy were reduced by 22% (95% confidence limits: 64% reduction to 67% excess), and the effects on pulmonary embolism were uninterpretable due to the small number of events recorded." Dextran 40 given for a period of 6 days after acute ischaemic stroke appeared to have no Prophylaxis against deep venous thrombosis and pulmonary embolism in stroke patients 211 therapy in preventing pulmonary embolism, and in the effect of such therapy on death, intracerebral haemorrhage and haemorrhagic transformation of cerebral infarctions. Table 4 summarizes the current evidence.
Stroke patients as a group are at high risk of venous thromboembolism. which remains a common cause of death and morbidity. Existing methods of DVT prophylaxis are undoubtedly underused and more attention from researchers and clinicians should be focused in this area.
